XML 34 R20.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Stock-Based Compensation | 12 Months Ended
--- | ---
Dec. 31, 2017
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] |
Stock-Based Compensation | Note 12. Stock-Based Compensation Employee Stock Plans Employee Stock Purchase Plan The Company maintains an Employee Stock Purchase Plan (the “Purchase Plan”), which is intended to qualify as an employee stock purchase plan within the meaning of Section 423(b) of the Internal Revenue Code. Under the Purchase Plan, the Company’s Board of Directors may authorize participation by eligible employees, including officers, in periodic offerings. Under the Purchase Plan eligible employee participants may purchase shares of common stock of the Company at a purchase price equal to 85% of the lower of the fair market value per share on the start date of the offering period or the fair market value per share on the purchase date. The Purchase Plan consists of a fixed offering period of 12 months with two purchase periods within each offering period. At December 31, 2017, the Company had 1.2 million shares available for future issuance. 2008 Equity Incentive Plan and Inducement Plan The Company also maintains an equity compensation plan to provide long-term incentives for employees, contractors, and members of its Board of Directors. The Company currently grants equity awards from one plan, the 2008 Equity Incentive Plan (the “2008 Plan”). The 2008 Plan allows for the issuance of non-statutory and incentive stock options, restricted stock, restricted stock units (“RSUs”), stock appreciation rights, other stock-related awards, and performance awards which may be settled in cash, stock, or other property. On June 6, 2012 and June 12, 2013, the stockholders approved amendments to the 2008 Plan (collectively the “Amended 2008 Plan”) such that the Amended 2008 Plan had reserved for issuance an amount not to exceed 19.5 million shares. On June 10, 2015, the Company’s stockholders approved an amendment and restatement of the 2008 Plan that increased the aggregate number of shares of common stock authorized for issuance under the 2008 Plan by 5,000,000 shares. On June 7, 2017, the Company’s stockholders approved an amendment and restatement of the 2008 Plan that increased the aggregate number of shares of common stock authorized for issuance under the 2008 Plan by 6,000,000 shares. Awards under the Amended 2008 Plan generally have a maximum term of 10 years from the date of the award. The Amended 2008 Plan generally requires options to be granted at 100% of the fair market value of the Company’s common stock subject to the option on the date of grant. Options granted by the Company to employees generally vest over four years. RSUs are measured based on the fair market value of the underlying stock on the date of grant and will generally vest over three years. Performance-based stock or cash awards granted under the Amended 2008 Plan are limited to either 500,000 shares of common stock or $1.0 million per recipient per calendar year. The attainment of any performance-based awards granted shall be conclusively determined by a committee designated by the Company’s Board of Directors. At December 31, 2017, no performance-based stock options were outstanding. On August 31, 2016, the Company’s Board of Directors adopted the Cerus Corporation Inducement Plan (the “Inducement Plan”), and reserved 1,250,000 shares of its common stock under the Inducement Plan to be used exclusively for the issuance of non-statutory stock options and restricted stock units to individuals who were not previously employees or directors of the Company, or who had experienced a bona fide period of non-employment, as an inducement material to the individual’s entry into employment with the Company within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules. The Inducement Plan was approved by the Company’s Board of Directors without stockholder approval pursuant to Rule 5635(c)(4), and the terms and conditions of the Inducement Plan are substantially similar to the Amended 2008 Plan. Effective June 7, 2017, the Company no longer issues shares from the Inducement Plan. At December 31, 2017, the Company had an aggregate of approximately 26.4 million shares of its common stock subject to outstanding options or RSUs, or remaining available for future issuance under the Amended 2008 Plan, of which approximately 17.1 million shares and 1.3 million shares were subject to outstanding options and outstanding RSUs, respectively, and approximately 8.0 million shares were available for future issuance under the Amended 2008 Plan. The Company’s policy is to issue new shares of common stock upon the exercise of options or vesting of RSUs. Activity under the Company’s equity incentive plans related to stock options is set forth below (in thousands except per share amounts):
|  | Number of Options Outstanding |  |  | Weighted Average Exercise Price per Share |
Balances at December 31, 2016 |  |  | 15,787 |  |  | $ | 4.39 |
Granted |  |  | 3,304 |  |  |  | 4.14 |
Forfeited |  |  | (1,087 | ) |  |  | 5.18 |
Expired |  |  | (322 | ) |  |  | 7.80 |
Exercised |  |  | (544 | ) |  |  | 3.11 |
Balances at December 31, 2017 |  |  | 17,138 |  |  |  | 4.27 |
Activity under the Company’s equity incentive plans related to RSUs is set forth below (in thousands except per share amounts):
|  | Number of Shares Outstanding |  |  | Weighted Average Grant Date Fair Value per Share |
Balances at December 31, 2016 |  |  | 739 |  |  | $ | 5.26 |
Granted |  |  | 918 |  |  |  | 4.18 |
Forfeited |  |  | (132 | ) |  |  | 4.53 |
Vested |  |  | (269 | ) |  |  | 5.35 |
Balances at December 31, 2017 |  |  | 1,256 |  |  |  | 4.53 |
The total fair value of RSUs as of their respective vesting dates, for the years ended December 31, 2017, 2016 and 2015, were $1.0 million, zero and zero, respectively. Information regarding the Company’s stock options outstanding, stock options vested and expected to vest, and stock options exercisable at December 31, 2017, was as follows (in thousands except weighted average exercise price and contractual term):
|  | Number of Shares |  |  | Weighted Average Exercise Price |  |  | Weighted Average Remaining Contractual Term (Years) |  |  | Aggregate Intrinsic Value |
Balances at December 31, 2017 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stock options outstanding |  |  | 17,138 |  |  | $ | 4.27 |  |  |  | 6.3 |  |  | $ | 3,691 |
Stock options vested and expected to vest |  |  | 16,911 |  |  |  | 4.27 |  |  |  | 6.2 |  |  |  | 3,681 |
Stock options exercisable |  |  | 12,109 |  |  |  | 4.12 |  |  |  | 5.4 |  |  |  | 3,487 |
The aggregate intrinsic value in the table above is calculated as the difference between the exercise price of the stock option and the Company’s closing stock price on the last trading day of each respective fiscal period. The total intrinsic value of options exercised for the years ended December 31, 2017, 2016 and 2015, was $0.6 million, $1.9 million and $1.2 million, respectively. Stock-based Compensation Expense Stock-based compensation expense recognized on the Company’s consolidated statements of operations for the years ended December 31, 2017, 2016 and 2015, was as follows (in thousands):
|  | Year Ended December 31, |
|  | 2017 |  |  | 2016 |  |  | 2015 |
Stock-based compensation expense by caption: |  |  |  |  |  |  |  |  |  |  |  |
Research and development |  | $ | 1,323 |  |  | $ | 1,091 |  |  | $ | 1,260 |
Selling, general and administrative |  |  | 8,032 |  |  |  | 6,974 |  |  |  | 5,470 |
Total stock-based compensation expense |  | $ | 9,355 |  |  | $ | 8,065 |  |  | $ | 6,730 |
Stock-based compensation expense in the above table does not reflect any income taxes as the Company has experienced a history of net losses since its inception and has a full valuation allowance on its deferred tax assets. In addition, there was neither income tax benefits realized related to stock-based compensation expense nor any stock-based compensation costs capitalized as part of an asset during the years ended December 31, 2017, 2016 and 2015. The Company has also not recorded any stock-based compensation associated with performance-based stock options during the years ended December 31, 2017, 2016 and 2015. As of December 31, 2017, the Company expects to recognize the remaining unamortized stock-based compensation expense of $9.7 million and $3.6 million, respectively, related to non-vested stock options and RSUs, net of estimated forfeitures, over an estimated remaining weighted average period of 2.4 years and 1.8 years, respectively. Valuation Assumptions for Stock-based Compensation The Company uses the Black-Scholes option pricing model to determine the grant-date fair value of stock options and employee stock purchase plan rights. The Black-Scholes option-pricing model is affected by the Company’s stock price, as well as assumptions regarding a number of complex and subjective variables, which include the expected term of the grants, actual and projected employee stock option exercise behaviors, including forfeitures, the Company’s expected stock price volatility, the risk-free interest rate and expected dividends. The Company recognizes the grant-date fair value of the stock award as stock-based compensation expense on a straight-line basis over the requisite service period, which is the vesting period, and is adjusted for estimated forfeitures. The expected life of the stock options is based on observed historical exercise patterns. Groups of employees having similar historical exercise behavior are considered separately for valuation purposes. The Company estimates stock option forfeitures based on historical data for employee groups. The total number of stock options expected to vest is adjusted by actual and estimated forfeitures. The expected volatility is estimated by using historical volatility of the Company’s common stock. The risk-free interest rate is based on the implied yield on a U.S. Treasury zero-coupon issue with a remaining term commensurate with the expected term of the option. The Company does not anticipate paying any cash dividends in the foreseeable future and therefore uses an expected dividend yield of zero. The weighted average assumptions used to value the Company’s stock-based awards for the years ended December 31, 2017, 2016 and 2015, was as follows:
|  | Year Ended December 31, |
|  | 2017 |  |  | 2016 |  |  | 2015 |
Stock Options: |  |  |  |  |  |  |  |  |  |  |  |
Expected term (in years) |  |  | 6.12 |  |  |  | 5.85 |  |  |  | 5.66 |
Estimated volatility |  | 47% |  |  | 49% |  |  | 56% |
Risk-free interest rate |  | 2.14% |  |  | 1.41% |  |  | 1.55% |
Expected dividend yield |  | 0% |  |  | 0% |  |  | 0% |
Employee Stock Purchase Plan Rights: |  |  |  |  |  |  |  |  |  |  |  |
Expected term (in years) |  |  | 0.92 |  |  |  | 0.76 |  |  |  | 0.75 |
Estimated volatility |  | 57% |  |  | 47% |  |  | 53% |
Risk-free interest rate |  | 1.08% |  |  | 0.55% |  |  | 0.28% |
Expected dividend yield |  | 0% |  |  | 0% |  |  | 0% |
The weighted average grant-date fair value of stock options granted during the years ended December 31, 2017, 2016 and 2015, was $1.98 per share, $2.55 per share and $2.35 per share, respectively. The weighted average grant-date fair value of employee stock purchase rights during the years ended December 31, 2017, 2016 and 2015, was $1.18 per share, $1.87 per share and $1.54 per share, respectively.

X
- Definition The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 50 -URI http://asc.fasb.org/subtopic&trid=2208855 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration